全文获取类型
收费全文 | 111130篇 |
免费 | 9084篇 |
国内免费 | 1660篇 |
专业分类
耳鼻咽喉 | 410篇 |
儿科学 | 1945篇 |
妇产科学 | 2141篇 |
基础医学 | 18411篇 |
口腔科学 | 3679篇 |
临床医学 | 19088篇 |
内科学 | 19313篇 |
皮肤病学 | 1255篇 |
神经病学 | 9254篇 |
特种医学 | 3295篇 |
外国民族医学 | 8篇 |
外科学 | 8715篇 |
综合类 | 7764篇 |
现状与发展 | 20篇 |
一般理论 | 4篇 |
预防医学 | 6715篇 |
眼科学 | 1384篇 |
药学 | 8379篇 |
65篇 | |
中国医学 | 1093篇 |
肿瘤学 | 8936篇 |
出版年
2024年 | 233篇 |
2023年 | 4905篇 |
2022年 | 7077篇 |
2021年 | 7878篇 |
2020年 | 8261篇 |
2019年 | 4741篇 |
2018年 | 4364篇 |
2017年 | 4286篇 |
2016年 | 4699篇 |
2015年 | 5205篇 |
2014年 | 9591篇 |
2013年 | 7168篇 |
2012年 | 6305篇 |
2011年 | 5630篇 |
2010年 | 5753篇 |
2009年 | 5184篇 |
2008年 | 2840篇 |
2007年 | 2987篇 |
2006年 | 2518篇 |
2005年 | 1978篇 |
2004年 | 1627篇 |
2003年 | 1537篇 |
2002年 | 1471篇 |
2001年 | 1518篇 |
2000年 | 1244篇 |
1999年 | 1291篇 |
1998年 | 1053篇 |
1997年 | 816篇 |
1996年 | 875篇 |
1995年 | 827篇 |
1994年 | 659篇 |
1993年 | 514篇 |
1992年 | 618篇 |
1991年 | 600篇 |
1990年 | 571篇 |
1989年 | 536篇 |
1988年 | 538篇 |
1987年 | 471篇 |
1986年 | 397篇 |
1985年 | 289篇 |
1984年 | 298篇 |
1983年 | 252篇 |
1982年 | 242篇 |
1981年 | 227篇 |
1980年 | 218篇 |
1979年 | 190篇 |
1978年 | 168篇 |
1977年 | 158篇 |
1976年 | 147篇 |
1974年 | 134篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
AimsThe effect of Origanum majorana tea consumption on motor and non-motor symptoms was investigated in patients with idiopathic Parkinson's disease, measured by validated tools.MethodsSixty patients with idiopathic Parkinson's disease and under conventional medication were enrolled voluntarily in the study. All participants were randomized on double-blind to placebo or Origanum majorana. Clinical assessment with validated tools (UPDRSIII, NMSS, and BDI) was done before Origanum majorana or placebo consumption (Day 0) and at the end of the experiment (Day 30).ResultsThe treatment groups were similar at baseline on demographic and clinical variables. During the course of study, nine participants withdrew for reasons of noncompliance and inability to follow-up. Fifty-one participants completed the study. Upon completion of 30 days of treatment, Origanum majorana tea consumption did not decrease the UPDRSIII score ([UPDRSIII] D0 = 18.76 ± 8.58, D30 = 16.52 ± 7.96, p = 0.069) at the p value was 0.07. However, a statistically significant improvement was noted in NMSS and BDI scores (p < 0.0001 and p < 0.0001, respectively). Assessment of the UPDRSIII, NMSS and BDI scores of the patients did not reflect any improvement with placebo. No side effect was detected during the study.ConclusionThese findings show improvement of depressive and non-motor signs in patients with Parkinson's disease in the group that consumed Origanum majorana tea in combination with conventional therapy. Improvement of motor signs may need an extended treatment period. However, more research with a large number of participants and lasting longer than 1 month is needed to argue these findings. 相似文献
82.
83.
84.
85.
86.
87.
《Clinical neurophysiology》2020,131(7):1444-1452
ObjectiveTo investigate cognitive functions in non-demented patients with early-onset Parkinson's disease (PD), and to compare PARK2 gene mutation carriers and non-carriers by means of event-related brain potentials (ERPs).MethodsThe participants comprised patients with early-onset PD (EOPD) and healthy controls (HC). Patients with EOPD were divided into two groups as carriers of known pathogenic variants of PARK2 gene (EOPD-PC) and non-carriers of genes involved in familial PD (EOPD-NC). ERP data were collected during auditory oddball and visual continuous performance test (CPT).ResultsBoth EOPD groups (EOPD-PC and EOPD-NC) displayed reduced and delayed P3 in response to oddball target and CPT NoGo. CPT Go P3 was reduced in EOPD-NC but not in EOPD-PC. Oddball target N1 was reduced and P2 was enhanced in both EOPD-PC and EOPD-NC. In both cognitive tasks, RTs were prolonged and accuracy was lower in EOPD-PC and EOPD-NC.ConclusionsWe found several EOPD-related neurophysiologic changes, implying impairments in cognitive functions. Pairwise comparisons between EOPD-PC and EOPD-NC revealed no significant ERP marker.SignificanceIn this study, the confounding effect of normative aging was somewhat excluded compared with many previous studies. In contrast with the many oddball studies in non-demented PD, we clearly observed reduced and prolonged P3 in early-onset PD. Our NoGo P3 findings also contribute to the limited ERP research concerning response inhibition. 相似文献
88.
89.
90.
《Transfusion medicine reviews》2019,33(4):207-216
The complement system plays an important role in varying types of disease, ranging from inflammatory and autoimmune disorders to immune deficiency states. In addition, new settings have emerged where complement analysis is of interest to monitor complement-directed therapy and aid identification of transplant complications. Therefore, it is critical that clinical laboratories offer optimized and timely complement analysis. This review presents a comprehensive overview of the most important complement analysis methods that are currently used. It also points to some areas within complement diagnostics where development is needed, for example, regarding certain analytes for which practical methods suitable for the routine laboratory are lacking. Furthermore, it contains a more detailed discussion on complement autoantibody assessment. The list of analyses providing clinically valuable information includes analysis of complement function, quantification of individual complement components and complement activation fragments, identification of autoantibodies to complement, as well as genetic complement analyses. There is still a shortage of commercially available methods suitable for high-throughput screening of complement deficiency and for assessment of complement activation, but development is under way. There is also ongoing work within the complement community to improve standardization of measurements, and recently, an extensive quality assurance program has been initiated. 相似文献